Lori A. Leslie, MD, lymphoma attending, discusses frontline treatment options in follicular lymphoma.
Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses frontline treatment options in follicular lymphoma.
Follicular lymphoma is a heterogeneous type of B-cell non-Hodgkin lymphoma with varied options for frontline management, says Leslie.
Currently, treatment selection is based on age, comorbidities, and disease aggressiveness, Leslie says. However, development of predictive and prognostic biomarkers remains an unmet need to identify which patients are at risk for poor outcomes.
Frontline treatment options consist of rituximab (Rituxan) as monotherapy or in combination with bendamustine, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), or obinutuzumab (Gazyva) with or without chemotherapy.
Additionally, maintenance therapy with a CD20 antibody is an option for patients who responded to chemoimmunotherapy, adds Leslie.